Normal view MARC view ISBD view

Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program. [Review]

MedStar author(s):

Citation: Current Diabetes Reports. 16(5):44, 2016 May.PMID: 27037706Institution: MedStar Health Research InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | Research Support, Non-U.S. Gov't | ReviewSubject headings: *Clinical Trials as Topic | *Glucagon-Like Peptide-1 Receptor/ag [Agonists] | Animals | Antibodies/im [Immunology] | Antibody Formation | Diabetes Mellitus, Type 2/dt [Drug Therapy] | Humans | Hypoglycemia/dt [Drug Therapy] | Hypoglycemic Agents/tu [Therapeutic Use]Year: 2016 ISSN:

1534-4827

Name of journal: Current diabetes reportsAbstract: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated benefits for patients with type 2 diabetes including A1C reduction and weight loss with minimal risk of hypoglycemia. This article provides an evidence-based update of safety and tolerability considerations for the clinical use of GLP-1RAs as a class, with a specific detailed review of data from the exenatide clinical trial development program, which has the longest history and availability of safety and tolerability data as the first-approved GLP-1RA. Specific areas covered include comparative risk of hypoglycemia, as well as pancreatic, thyroid, and cardiovascular safety data; clinical guidance regarding current safety and tolerability data is also reviewed.All authors: Aroda VR, Peng H, Want LLFiscal year: FY2016Digital Object Identifier:

http://dx.doi.org/10.1007/s11892-016-0728-4

Date added to catalog: 2017-03-07

Holdings ( 1 )
Title notes ( 2 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	27037706	Available		27037706

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated benefits for patients with type 2 diabetes including A1C reduction and weight loss with minimal risk of hypoglycemia. This article provides an evidence-based update of safety and tolerability considerations for the clinical use of GLP-1RAs as a class, with a specific detailed review of data from the exenatide clinical trial development program, which has the longest history and availability of safety and tolerability data as the first-approved GLP-1RA. Specific areas covered include comparative risk of hypoglycemia, as well as pancreatic, thyroid, and cardiovascular safety data; clinical guidance regarding current safety and tolerability data is also reviewed.

English